PT  - JOURNAL ARTICLE
AU  - Saponi-Cortes, Jose Maria R
AU  - Rivas, Maria Dolores
AU  - Calle, Fernando
AU  - Sanchez Muñoz-Torrero, Juan F
AU  - Costo, Alberto
AU  - Martin, Carlos
AU  - Zamorano, Jose
TI  - IFNL4 genetic variant can predispose to COVID-19
AID  - 10.1101/2021.03.01.21252696
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.03.01.21252696
4099  - http://medrxiv.org/content/early/2021/04/09/2021.03.01.21252696.short
4100  - http://medrxiv.org/content/early/2021/04/09/2021.03.01.21252696.full
AB  - Interferon lambda 4 (IFNλ4) has shown antiviral activity against RNA viruses, including some coronaviruses. Besides, genetic variants of IFNL4 can be predictive of clearance of RNA viruses. However, little is known about the effect of these genetic variants on SARS-CoV-2 infection. In this study, we investigated whether there was a relationship of the rs12979860 polymorphism of IFNL4 with COVID-19. We found that the T allele of rs12979860 was overrepresented in the COVID-19 patients with regard to the general population without this disease (36.16% vs. 26.40%, p=6.4×10−4; OR=0.633; 95% CI=0.487,0.824), suggesting this allele could be a risk factor to COVID-19. Accordingly, the CC genotype was significantly lower in COVID-19 patients compared to controls (37.85% vs. 55.51%, p=8×10−5; OR=0.488; 95% CI=0.342,0.698). These results were not affected by sex, age, and disease severity in patients with COVID-19. Our findings suggest that, like other infectious diseases caused by RNA viruses, genetic variants of IFNL4 may predispose to COVID-19. Confirmation of our results could have a substantial impact on the prognosis and treatment of this disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was partially funded by the Junta de Extremadura Grant GR18105 MDRivas is supported by the Spanish Ministerio de Economia, Industria y Competitividad Grant PTA2017-13904-I and FUNDESALUDAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Ethical Committee for Clinical Research of CaceresAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNo additional data but the included in the article. The data that support the findings of this study are available from the corresponding author upon request